Tempus Q2 Revenue Surges, Full-Year Guidance Unchanged; Personalis Merger Pending

What happened

Tempus AI reported second quarter 2026 results highlighted by exceptional growth in its Oncology Diagnostic and Data & Applications segments. CEO Eric Lefkofsky cited investments in AI as driving the best growth rates in the company's two largest businesses. The company reaffirmed its full-year 2026 guidance of $1.59 ‑ $1.60 billion in revenue and approximately $65 million in adjusted EBITDA, signaling confidence despite the proposed Personalis merger. The release likely showed continued top‑line momentum alongside a still‑wide GAAP net loss, consistent with recent trends. The Personalis transaction, which will add minimal residual disease testing capabilities, remains pending regulatory approvals and has not yet contributed to operating results.

Implication

Tempus’s Q2 print validates the core diagnostics and data flywheel, with management holding guidance steady after the Personalis announcement. Still, the investment case rests on the successful integration of Personalis and the company’s ability to narrow GAAP losses—a scenario that remains unproven. At current prices, the stock already discounts continued revenue strength, leaving limited upside until operating leverage becomes clearer. We maintain our WAIT rating and would consider adding only on a pullback to an attractive entry around $42.

Thesis delta

The Q2 results confirm robust top‑line momentum and management’s commitment to its 2026 financial targets, strengthening the base case. However, the primary drivers of our WAIT rating—GAAP losses, the pending Personalis merger, and the need for sustained operating‑leverage proof—remain unchanged. As such, the thesis does not shift materially.